CORTAGEN

Cognitive EnhancementResearch Only

Extremely limited human data with only one published human study and no controlled trials. The research is mostly theoretical and preliminary animal work.

Primarily studied by gerontology researchers investigating peptide-based interventions for brain aging and neuroscientists exploring epigenetic approaches to neuroprotection.

FDA Status

Research Only

Since Feb 2026

Evidence

Limited data

Studies

13 total, 1 human

What is CORTAGEN?

Part of Vladimir Khavinson's bioregulator peptide family, this tripeptide was developed specifically to target brain cortex cells and has become a focus for researchers studying age-related neurodegeneration. The peptide emerged from decades of Soviet-era research into organ-specific regulatory compounds and is now primarily investigated by gerontology researchers and neuroscientists exploring non-pharmacological approaches to cognitive aging.

The peptide appears to work by binding directly to specific DNA sequences in cortical brain cells, essentially acting like a molecular switch that can turn certain genes on or off. This genetic modulation may help aging neurons maintain better function and resist damage, though the exact pathways involved are still being mapped out by researchers.

What the Research Shows

With only 1 human study among 13 total publications and no randomized controlled trials, the evidence base remains largely preclinical.

The evidence base for CORTAGEN consists of 13 total studies with only 1 human study and no randomized controlled trials. Available findings indicate that short peptides may modify epigenetic markers in aged chromatin and alter lymphocyte structure in elderly subjects, while in vitro and animal studies suggest potential effects on oxidative stress reduction and interleukin-2 gene expression, though human clinical efficacy remains largely unestablished.